在临港新片区医疗器械创新中心组织下，来自俄罗斯、白俄罗斯、哈萨克斯坦、吉尔吉斯斯坦、巴基斯 坦等十多个国家和地区的知名高校、医疗机构及行业企业代表组成的代表团来到上海浦东医院考察。此 次访问旨在深化国际医疗合作，共同探索跨境医疗服务与创新医疗器械领域的发展机遇。 上海浦东医院院长李济宇30日对记者表示，此次代表团队来访交流，意味着上海浦东医院临港院区在国 际医疗资源对接，有效拓展目标服务群体方面，实现新的突破，将助力临港院区建设成为上海跨境医疗 的重要引擎和消费升级趋势下的一个国际化、市场化的"康-旅"联动示范项目。 俄罗斯国际商务合作国家协调中心总经理卡拉谢夫·米哈伊尔(Karasev Mikhail)表示，俄罗斯及周边国家 对高品质中医诊疗服务的需求日益增长。他希望与上海浦东医院共同开展在俄罗斯及独联体国家的商务 医疗巡诊；探索融合中医药诊疗特色的国际医疗旅游、跨境医疗服务领域的多元合作模式；并提议在创 新医疗器械安全验证方面建立上海浦东医院与俄罗斯知名高校及医疗机构的联合检测中心。 （文章来源：中国新闻网） 今年3月，临港新片区跨境医疗方案发布会暨首批项目签约揭牌仪式举行，上海浦东医院作为首批跨境 医疗 ...

德国籍中医马赛丽。 蔡肖翰摄 把脉号脉、询问病症细节、向患者介绍汤剂煎煮方法……走进位于北京市朝阳区的一家中医诊所，德国 籍中医马赛丽（Christin Masseli）正忙着给来自不同国家的患者看诊。她熟练掌握中医各类诊疗手法， 针灸、艾灸、穴位按压，一整套流程行云流水。 马赛丽在中国学中医、行中医已超过10年，拥有北京中医药大学学士和硕士学位，能使用德语、英语和 汉语等多国语言与患者流畅交流。她还积极传播中医基本理念，让更多外国人领略中华传统医学魅力， 助力中医药服务更具"国际范儿"。 漂洋过海，学习东方古老智慧 为了赶上班上中国同学的步伐，马赛丽不断向老师和同学请教，课余时间泡在图书馆，笔记密密麻麻。 就这样，经过多年寒窗，马赛丽学会了经络穴位、中药配伍，也练就了精准望闻问切的本领。 "这段学习经历让我的'中医梦'走向现实。"马赛丽说，"我掌握了看诊技能，还感悟到中医不仅是疗法， 更是一门与自然对话的古老智慧，每一味草药都承载着医者的良苦用心。" "你知道吗？中国有中草药，德国有'德草药'"。 谈到为何与中医结缘，马赛丽直言与小时候的经历分不开："德国有使用草药治病的传统。很多家庭会 在屋边种植草药，我 ...

青岛中医药传承创新基地项目一期工程占地约150亩，总建筑面积约15万平米，由14个单体建筑组成， 涵盖实验楼、研发孵化楼、科研保障楼、生活服务楼、康复楼、食堂、国医堂和体检中心等多元功能区 域。整体包括东西两个板块，西区(研发孵化区)以太极八卦为核心，红砖与中式元素交相辉映。东区(医 疗康养区)借鉴古典造园手法，传承传统院落形制与中医文脉，研发孵化楼采用圆形螺旋上升结构，具 象演绎传统哲学理念。 齐鲁晚报.齐鲁壹点记者赵波通讯员李青健 日前，青岛中医药传承创新基地项目一期工程顺利通过竣工验收。一座承载着中医药传承与创新使命的 现代化园区展露新颜。 康养楼内更是别有洞天。康养公寓温馨宜居，116户的规模为人们提供了舒适的康养环境；机构养老区 内设有养老床位162张，将为老年人带来贴心的照护；医疗中转床位区域也已准备就绪，随时为患者提 供过渡性医疗服务。 国医堂和体检中心，建筑面积约1.3万平方米，内设体检中心、放射检查中心、中医康复中心、中医内 科、中医外科、针灸推拿科等多个专业诊疗板块，由高实集团与山东中医药大学拟共同合作成立一家中 医院，将依托山东中医药大学强大的中医专家资源，为青岛及周边地区患者，提供疑难 ...

Group 1 - The event "Investors Walk into Listed Companies" aims to enhance communication between investors and companies, promoting financial knowledge and rational investment [1] - Yuyuan Group, rooted in China, focuses on family happiness consumption, with a diverse portfolio including gold jewelry, cultural dining, liquor, health, and fashion [1] - The company has been optimizing its business layout and expanding overseas markets, aiming to create a global fashion cultural showcase [2] Group 2 - The CFO of Tonghanchuntang emphasized the brand's commitment to traditional Chinese medicine, focusing on innovation and the development of health products [2] - The event included a tour of Yuyuan's gold jewelry store, showcasing various products that blend traditional culture with modern design [3] - Yuyuan Group plans to enhance Tonghanchuntang's brand value by focusing on the food-medicine integration field and expanding distribution channels [4] Group 3 - The company is confident in its long-term development in the gold jewelry sector despite fluctuations in gold prices, implementing strategies to optimize product structure and expand sales channels [3] - The event facilitated a deeper understanding of Yuyuan Group's achievements in the gold and health sectors, strengthening investor relations [4]

孟牛安教授指出：患儿体内痰、热、瘀三邪相互交杂，病理产物堆积在鼻咽喉，对腺样体产生直接刺 激，引起腺体异常增生肥大。 治疗时需要着眼于脾胃虚弱、肺脏娇嫩、气血不足等问题，从整体入手，通过调理脾胃、化痰清热、增 强免疫，不仅能缓解症状、缩小腺体，还可以改善孩子的全身健康状况。 辨证施治，临床实践显疗效 腺样体肥大作为近年来发病率日益增长的儿科常见病，受到家长与社会各界的广泛关注，但传统的手术 切除治疗方式备受争议，患儿不仅需要承受各类手术风险，较高的术后复发率也让人望而却步。 溯源寻因，创新中医治疗理念 针对腺样体肥大缺乏有效治疗方案的现况，云太医郑州分院(素朴中医院)特邀儿科专家孟牛安教授深耕 儿科近40年，携手云太医互联网医疗管理平台，致力于守护千万儿童的健康成长。他始终秉持细心、耐 心的职业态度，潜心研究腺样体肥大的中医药诊疗方案，为患儿提供了安全有效的中医整体化治疗途 径。 作为现代化医疗服务领路人，云太医始终以"传承中医智慧，守护全民健康" 为使命，建立起全面化中 医互联网医疗平台。与全国近百位名医专家协作，覆盖儿科、妇科、慢病、情志等众多领域，打破地域 限制，构建了覆盖诊前、诊中、诊后的立体化服务体 ...

Summary of Conference Call Company and Industry Overview - The conference call discusses the performance of a healthcare company, specifically in the traditional Chinese medicine sector, for the year 2024. The company has faced challenges but has achieved significant growth in revenue and adjusted profits despite the environment [1][2]. Key Financial Highlights - Revenue growth exceeded 30%, with adjusted profits surpassing 400 million RMB, marking a 31.4% increase [2][5]. - The return on equity (ROE) was highlighted, although specific figures were not provided [2]. - The company maintained a gross margin of 30.8%, slightly up from 30.6% in the previous year, indicating stable profitability [5]. - Free cash flow reached 236 million RMB, a 64% year-over-year increase, reflecting strong operational cash generation [7]. Business Expansion and Partnerships - The company established partnerships with 8 new medical institutions, bringing the total to 28 [3]. - A total of 21 new stores were opened, exceeding the planned target of 3 cities, including the first international location in Singapore [3]. - The company has invested over 400 million RMB in shareholder returns, including stock buybacks and dividends [4][8]. User and Membership Growth - User metrics showed rapid growth, with membership revenue increasing significantly, accounting for 41% of total revenue in 2023 and rising in 2024 [10][11]. - The company reported a stable increase in customer retention and spending per visit, indicating strong brand loyalty [10]. Doctor and Staff Development - The number of doctors increased by 25%, with a notable rise in senior-level physicians [15]. - The company is focusing on training and retaining talent, with a structured pathway for career advancement for new graduates [43][44]. AI and Technological Integration - The company is leveraging AI to enhance its service delivery, with plans to develop a proprietary AI model for traditional Chinese medicine [31][55]. - AI applications are expected to improve diagnostic accuracy and operational efficiency, with a focus on integrating AI into patient care [34][55]. ESG Contributions - The company has made significant contributions in the ESG space, including community health initiatives and cultural events promoting traditional Chinese medicine [19]. Future Outlook and Strategic Direction - The company plans to continue expanding internationally, particularly in Singapore and Hong Kong, while also focusing on AI development [24][26]. - Revenue growth is projected to be around 25% for the upcoming year, with ongoing investments in AI and technology [56][59]. Additional Insights - The company is adapting to regulatory changes in the healthcare sector, positioning itself as a leader in compliance and operational excellence [21]. - There is a strong emphasis on maintaining high-quality service standards and enhancing the patient experience through innovative solutions [39][46]. This summary encapsulates the key points discussed during the conference call, highlighting the company's financial performance, growth strategies, and future outlook in the healthcare industry.